BiotechTube
Sciomics

Sciomics

Heidelberg, Germany· Est.
sciomics.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Sciomics is a Heidelberg-based proteomics service and product company leveraging a proprietary antibody microarray platform for high-content protein analysis. The company operates a dual model, offering fee-for-service profiling to external researchers while also developing its own internal pipeline of diagnostic biomarker panels, most notably scioAKI for early detection of acute kidney injury. With a focus on translating proteomic data into clinically actionable tools, Sciomics is positioning itself at the intersection of research services and in vitro diagnostic (IVD) development to enable precision medicine.

Acute Kidney InjuryOncologyInfectious DiseasesOrgan Failure

Technology Platform

Proprietary antibody microarray platform for high-content protein profiling (>1,400 proteins) and post-translational modification analysis (phosphorylation, ubiquitination). Fully immune-based for easy translation to diagnostic assays like ELISA or CLIA.

Opportunities

The global shift towards precision medicine and biomarker-driven drug development creates strong demand for high-content proteomic services.
The significant unmet need in AKI diagnosis, affecting over 50% of ICU patients, presents a major commercial opportunity for its lead scioAKI panel as a point-of-care IVD test.
The antibody-based platform allows for straightforward translation of discoveries into widely used diagnostic formats, accelerating the path to market.

Risk Factors

Intense competition from both service providers and alternative proteomic technologies, particularly advancing mass spectrometry, threatens market position.
The high cost, regulatory complexity, and execution risk of developing and commercializing an IVD product from scratch, as planned for scioAKI, is a significant financial and operational hurdle.
Dependency on the research funding environment for its service revenue creates potential volatility.

Competitive Landscape

Sciomics competes in the proteomics services space against large CROs, mass spectrometry core facilities, and other multiplex immunoassay providers (e.g., Olink, SomaLogic). Its diagnostic ambitions place it against established IVD companies with AKI tests (e.g., BioPorto with its NGAL test) and numerous biotechs developing novel biomarkers. Its key differentiator is the integrated service-to-diagnostic model based on a translatable antibody platform.

More companies in Proteomics & Protein Engineering →More companies in Germany →